[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100118492":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":35,"centralContacts":27,"locations":39,"responsibleParty":53,"collaborators":27,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":27,"acronym":27,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":27,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":76,"whyStopped":27,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":27,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"1","EXPERIMENTAL","ABT-143 capsules 20\u002F135 mg",[13],"Drug: ABT-143",{"label":15,"type":16,"description":17,"interventionNames":18},"2","ACTIVE_COMPARATOR","ABT-335 135 mg and rosuvastatin 20 mg",[19,20],"Drug: ABT-335","Drug: rosuvastatin",[22,28,31],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","ABT-143","once, see arm description for more information",[9],null,{"type":23,"name":29,"description":25,"armGroupLabels":30,"otherNames":27},"ABT-335",[15],{"type":23,"name":32,"description":33,"armGroupLabels":34,"otherNames":27},"rosuvastatin","once, see arm description for more detail",[15],[36],{"name":37,"affiliation":5,"role":38},"Torbjörn Lundström, MD","STUDY_DIRECTOR",[40],{"facility":41,"status":27,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":27},"Site Reference ID\u002FInvestigator# 14762","Orlando","Florida","32809","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-81.37924,28.53834,{"lat":51,"lon":50},{"type":54,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100118492","phase-1-comparison-of-the-bioavailability-of-fenofibric-acid-and-rosuvastatin-from-abt-143-relative-to-that-from-the-coadministration-of-abt-335-fenofibric-acid-and-rosuvastatin-calcium-100118492",false,"NCT00808678","Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium","Inclusion Criteria:\n\n1. A condition of general good health\n2. BMI 19 to 29\n\nExclusion Criteria:\n\n1. Currently enrolled in another clinical study\n2. Females who are pregnant or breast-feeding",true,"ALL","18 Years","55 Years",{"count":66,"type":67},90,"ACTUAL","INTERVENTIONAL",[70],"PHASE1","The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.",[73],"Healthy",[75],"Adverse Events","COMPLETED","2012-09-27",{"date":79,"type":80},"2012-09-28","ESTIMATED",{"date":82,"type":27},"2008-12",{"name":5,"class":6},1]